Table of Content

1 Drugs for HIV Market Overview
1.1 Product Overview and Scope of Drugs for HIV
1.2 Drugs for HIV Segment by Type
1.2.1 Global Drugs for HIV Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
1.2.3 Integrase Inhibitors
1.2.4 Combination HIV Medicines
1.2.5 Others
1.3 Drugs for HIV Segment by Application
1.3.1 Drugs for HIV Sales Comparison by Application: (2021-2027)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Global Drugs for HIV Market Size Estimates and Forecasts
1.4.1 Global Drugs for HIV Revenue 2016-2027
1.4.2 Global Drugs for HIV Sales 2016-2027
1.4.3 Drugs for HIV Market Size by Region: 2016 Versus 2021 Versus 2027

2 Drugs for HIV Market Competition by Manufacturers
2.1 Global Drugs for HIV Sales Market Share by Manufacturers (2016-2021)
2.2 Global Drugs for HIV Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Drugs for HIV Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Drugs for HIV Manufacturing Sites, Area Served, Product Type
2.5 Drugs for HIV Market Competitive Situation and Trends
2.5.1 Drugs for HIV Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Drugs for HIV Players Market Share by Revenue
2.5.3 Global Drugs for HIV Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Drugs for HIV Retrospective Market Scenario by Region
3.1 Global Drugs for HIV Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Drugs for HIV Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Drugs for HIV Market Facts & Figures by Country
3.3.1 North America Drugs for HIV Sales by Country
3.3.2 North America Drugs for HIV Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Drugs for HIV Market Facts & Figures by Country
3.4.1 Europe Drugs for HIV Sales by Country
3.4.2 Europe Drugs for HIV Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Drugs for HIV Market Facts & Figures by Region
3.5.1 Asia Pacific Drugs for HIV Sales by Region
3.5.2 Asia Pacific Drugs for HIV Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Drugs for HIV Market Facts & Figures by Country
3.6.1 Latin America Drugs for HIV Sales by Country
3.6.2 Latin America Drugs for HIV Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Drugs for HIV Market Facts & Figures by Country
3.7.1 Middle East and Africa Drugs for HIV Sales by Country
3.7.2 Middle East and Africa Drugs for HIV Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Drugs for HIV Historic Market Analysis by Type
4.1 Global Drugs for HIV Sales Market Share by Type (2016-2021)
4.2 Global Drugs for HIV Revenue Market Share by Type (2016-2021)
4.3 Global Drugs for HIV Price by Type (2016-2021)

5 Global Drugs for HIV Historic Market Analysis by Application
5.1 Global Drugs for HIV Sales Market Share by Application (2016-2021)
5.2 Global Drugs for HIV Revenue Market Share by Application (2016-2021)
5.3 Global Drugs for HIV Price by Application (2016-2021)

6 Key Companies Profiled
6.1 ViiV Healthcare
6.1.1 ViiV Healthcare Corporation Information
6.1.2 ViiV Healthcare Description and Business Overview
6.1.3 ViiV Healthcare Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.1.4 ViiV Healthcare Product Portfolio
6.1.5 ViiV Healthcare Recent Developments/Updates
6.2 Gilead Sciences, Inc
6.2.1 Gilead Sciences, Inc Corporation Information
6.2.2 Gilead Sciences, Inc Description and Business Overview
6.2.3 Gilead Sciences, Inc Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Gilead Sciences, Inc Product Portfolio
6.2.5 Gilead Sciences, Inc Recent Developments/Updates
6.3 Merck Sharp & Dohme Corp
6.3.1 Merck Sharp & Dohme Corp Corporation Information
6.3.2 Merck Sharp & Dohme Corp Description and Business Overview
6.3.3 Merck Sharp & Dohme Corp Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Merck Sharp & Dohme Corp Product Portfolio
6.3.5 Merck Sharp & Dohme Corp Recent Developments/Updates
6.4 Bristol-Myers Squibb Company
6.4.1 Bristol-Myers Squibb Company Corporation Information
6.4.2 Bristol-Myers Squibb Company Description and Business Overview
6.4.3 Bristol-Myers Squibb Company Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bristol-Myers Squibb Company Product Portfolio
6.4.5 Bristol-Myers Squibb Company Recent Developments/Updates
6.5 Janssen Pharmaceuticals, Inc.
6.5.1 Janssen Pharmaceuticals, Inc. Corporation Information
6.5.2 Janssen Pharmaceuticals, Inc. Description and Business Overview
6.5.3 Janssen Pharmaceuticals, Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Janssen Pharmaceuticals, Inc. Product Portfolio
6.5.5 Janssen Pharmaceuticals, Inc. Recent Developments/Updates
6.6 Theratechnologies Inc.
6.6.1 Theratechnologies Inc. Corporation Information
6.6.2 Theratechnologies Inc. Description and Business Overview
6.6.3 Theratechnologies Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Theratechnologies Inc. Product Portfolio
6.6.5 Theratechnologies Inc. Recent Developments/Updates
6.7 Mylan Pharmaceuticals Inc.
6.6.1 Mylan Pharmaceuticals Inc. Corporation Information
6.6.2 Mylan Pharmaceuticals Inc. Description and Business Overview
6.6.3 Mylan Pharmaceuticals Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Mylan Pharmaceuticals Inc. Product Portfolio
6.7.5 Mylan Pharmaceuticals Inc. Recent Developments/Updates
6.8 Genentech, Inc.
6.8.1 Genentech, Inc. Corporation Information
6.8.2 Genentech, Inc. Description and Business Overview
6.8.3 Genentech, Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Genentech, Inc. Product Portfolio
6.8.5 Genentech, Inc. Recent Developments/Updates
6.9 AbbVie Inc.
6.9.1 AbbVie Inc. Corporation Information
6.9.2 AbbVie Inc. Description and Business Overview
6.9.3 AbbVie Inc. Drugs for HIV Sales, Revenue and Gross Margin (2016-2021)
6.9.4 AbbVie Inc. Product Portfolio
6.9.5 AbbVie Inc. Recent Developments/Updates

7 Drugs for HIV Manufacturing Cost Analysis
7.1 Drugs for HIV Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Drugs for HIV
7.4 Drugs for HIV Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Drugs for HIV Distributors List
8.3 Drugs for HIV Customers

9 Drugs for HIV Market Dynamics
9.1 Drugs for HIV Industry Trends
9.2 Drugs for HIV Growth Drivers
9.3 Drugs for HIV Market Challenges
9.4 Drugs for HIV Market Restraints

10 Global Market Forecast
10.1 Drugs for HIV Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Drugs for HIV by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Drugs for HIV by Type (2022-2027)
10.2 Drugs for HIV Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Drugs for HIV by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Drugs for HIV by Application (2022-2027)
10.3 Drugs for HIV Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Drugs for HIV by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Drugs for HIV by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Drugs for HIV Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Drugs for HIV Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Drugs for HIV Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Drugs for HIV Covered in This Study
Table 5. Global Drugs for HIV Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Drugs for HIV Sales Share by Manufacturers (2016-2021)
Table 7. Global Drugs for HIV Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Drugs for HIV Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Drugs for HIV Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Drugs for HIV Manufacturing Sites and Area Served
Table 11. Manufacturers Drugs for HIV Product Type
Table 12. Global Drugs for HIV Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Drugs for HIV by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Drugs for HIV as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Drugs for HIV Sales by Region (2016-2021) & (K Units)
Table 16. Global Drugs for HIV Sales Market Share by Region (2016-2021)
Table 17. Global Drugs for HIV Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Drugs for HIV Sales by Country (2016-2021) & (K Units)
Table 19. North America Drugs for HIV Sales Market Share by Country (2016-2021)
Table 20. North America Drugs for HIV Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Drugs for HIV Revenue Market Share by Country (2016-2021)
Table 22. Europe Drugs for HIV Sales by Country (2016-2021) & (K Units)
Table 23. Europe Drugs for HIV Sales Market Share by Country (2016-2021)
Table 24. Europe Drugs for HIV Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Drugs for HIV Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Drugs for HIV Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Drugs for HIV Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Drugs for HIV Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Drugs for HIV Revenue Market Share by Region (2016-2021)
Table 30. Latin America Drugs for HIV Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Drugs for HIV Sales Market Share by Country (2016-2021)
Table 32. Latin America Drugs for HIV Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Drugs for HIV Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Drugs for HIV Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Drugs for HIV Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Drugs for HIV Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Drugs for HIV Revenue Market Share by Country (2016-2021)
Table 38. Global Drugs for HIV Sales (K Units) by Type (2016-2021)
Table 39. Global Drugs for HIV Sales Market Share by Type (2016-2021)
Table 40. Global Drugs for HIV Revenue (Million US$) by Type (2016-2021)
Table 41. Global Drugs for HIV Revenue Share by Type (2016-2021)
Table 42. Global Drugs for HIV Price (US$/Unit) by Type (2016-2021)
Table 43. Global Drugs for HIV Sales (K Units) by Application (2016-2021)
Table 44. Global Drugs for HIV Sales Market Share by Application (2016-2021)
Table 45. Global Drugs for HIV Revenue (Million US$) by Application (2016-2021)
Table 46. Global Drugs for HIV Revenue Share by Application (2016-2021)
Table 47. Global Drugs for HIV Price (US$/Unit) by Application (2016-2021)
Table 48. ViiV Healthcare Corporation Information
Table 49. ViiV Healthcare Description and Business Overview
Table 50. ViiV Healthcare Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. ViiV Healthcare Drugs for HIV Product
Table 52. ViiV Healthcare Recent Developments/Updates
Table 53. Gilead Sciences, Inc Corporation Information
Table 54. Gilead Sciences, Inc Description and Business Overview
Table 55. Gilead Sciences, Inc Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Gilead Sciences, Inc Drugs for HIV Product
Table 57. Gilead Sciences, Inc Recent Developments/Updates
Table 58. Merck Sharp & Dohme Corp Corporation Information
Table 59. Merck Sharp & Dohme Corp Description and Business Overview
Table 60. Merck Sharp & Dohme Corp Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Merck Sharp & Dohme Corp Drugs for HIV Product
Table 62. Merck Sharp & Dohme Corp Recent Developments/Updates
Table 63. Bristol-Myers Squibb Company Corporation Information
Table 64. Bristol-Myers Squibb Company Description and Business Overview
Table 65. Bristol-Myers Squibb Company Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Bristol-Myers Squibb Company Drugs for HIV Product
Table 67. Bristol-Myers Squibb Company Recent Developments/Updates
Table 68. Janssen Pharmaceuticals, Inc. Corporation Information
Table 69. Janssen Pharmaceuticals, Inc. Description and Business Overview
Table 70. Janssen Pharmaceuticals, Inc. Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Janssen Pharmaceuticals, Inc. Drugs for HIV Product
Table 72. Janssen Pharmaceuticals, Inc. Recent Developments/Updates
Table 73. Theratechnologies Inc. Corporation Information
Table 74. Theratechnologies Inc. Description and Business Overview
Table 75. Theratechnologies Inc. Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. Theratechnologies Inc. Drugs for HIV Product
Table 77. Theratechnologies Inc. Recent Developments/Updates
Table 78. Mylan Pharmaceuticals Inc. Corporation Information
Table 79. Mylan Pharmaceuticals Inc. Description and Business Overview
Table 80. Mylan Pharmaceuticals Inc. Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. Mylan Pharmaceuticals Inc. Drugs for HIV Product
Table 82. Mylan Pharmaceuticals Inc. Recent Developments/Updates
Table 83. Genentech, Inc. Corporation Information
Table 84. Genentech, Inc. Description and Business Overview
Table 85. Genentech, Inc. Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 86. Genentech, Inc. Drugs for HIV Product
Table 87. Genentech, Inc. Recent Developments/Updates
Table 88. AbbVie Inc. Corporation Information
Table 89. AbbVie Inc. Description and Business Overview
Table 90. AbbVie Inc. Drugs for HIV Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 91. AbbVie Inc. Drugs for HIV Product
Table 92. AbbVie Inc. Recent Developments/Updates
Table 93. Production Base and Market Concentration Rate of Raw Material
Table 94. Key Suppliers of Raw Materials
Table 95. Drugs for HIV Distributors List
Table 96. Drugs for HIV Customers List
Table 97. Drugs for HIV Market Trends
Table 98. Drugs for HIV Growth Drivers
Table 99. Drugs for HIV Market Restraints
Table 100. Global Drugs for HIV Sales Forecast by Type (2022-2027) & (K Units)
Table 101. Global Drugs for HIV Sales Market Share Forecast by Type (2022-2027)
Table 102. Global Drugs for HIV Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 103. Global Drugs for HIV Revenue Market Share Forecast by Type (2022-2027)
Table 104. Global Drugs for HIV Sales Forecast by Application (2022-2027) & (K Units)
Table 105. Global Drugs for HIV Sales Market Share Forecast by Application (2022-2027)
Table 106. Global Drugs for HIV Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 107. Global Drugs for HIV Revenue Market Share Forecast by Application (2022-2027)
Table 108. Global Drugs for HIV Sales Forecast by Region (2022-2027) & (K Units)
Table 109. Global Drugs for HIV Sales Market Share Forecast by Region (2022-2027)
Table 110. Global Drugs for HIV Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 111. Global Drugs for HIV Revenue Market Share Forecast by Region (2022-2027)
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Drugs for HIV
Figure 2. Global Drugs for HIV Market Share by Type in 2020 & 2027
Figure 3. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Product Picture
Figure 4. Integrase Inhibitors Product Picture
Figure 5. Combination HIV Medicines Product Picture
Figure 6. Others Product Picture
Figure 7. Global Drugs for HIV Market Share by Application in 2020 & 2027
Figure 8. Hospital Pharmacies
Figure 9. Retail Pharmacies
Figure 10. Online Pharmacies
Figure 11. Others
Figure 12. Global Drugs for HIV Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Drugs for HIV Market Size 2016-2027 (US$ Million)
Figure 14. Global Drugs for HIV Sales 2016-2027 (K Units)
Figure 15. Global Drugs for HIV Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 16. Drugs for HIV Sales Share by Manufacturers in 2020
Figure 17. Global Drugs for HIV Revenue Share by Manufacturers in 2020
Figure 18. The Global 5 and 10 Largest Drugs for HIV Players: Market Share by Revenue in 2020
Figure 19. Drugs for HIV Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 20. Global Drugs for HIV Sales Market Share by Region (2016-2021)
Figure 21. Global Drugs for HIV Sales Market Share by Region in 2020
Figure 22. Global Drugs for HIV Revenue Market Share by Region (2016-2021)
Figure 23. Global Drugs for HIV Revenue Market Share by Region in 2020
Figure 24. U.S. Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. Canada Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. Germany Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. France Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. U.K. Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. Italy Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Russia Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. China Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. Japan Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. South Korea Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. India Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Australia Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Taiwan Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Indonesia Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Thailand Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Malaysia Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Philippines Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Vietnam Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Mexico Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Brazil Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Argentina Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. Turkey Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Saudi Arabia Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 47. UAE Drugs for HIV Revenue Growth Rate (2016-2021) (US$ Million)
Figure 48. Sales Market Share of Drugs for HIV by Type (2016-2021)
Figure 49. Sales Market Share of Drugs for HIV by Application (2016-2021)
Figure 50. Sales Market Share of Drugs for HIV by Application in 2020
Figure 51. Revenue Share of Drugs for HIV by Application (2016-2021)
Figure 52. Revenue Share of Drugs for HIV by Application in 2020
Figure 53. Manufacturing Cost Structure of Drugs for HIV
Figure 54. Manufacturing Process Analysis of Drugs for HIV
Figure 55. Drugs for HIV Industrial Chain Analysis
Figure 56. Channels of Distribution
Figure 57. Distributors Profiles
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed